Amnioinfusion for third trimester preterm premature rupture of membranes

G. Justus Hofmeyr, Ahizechukwu Eke, Theresa A. Lawrie

Research output: Contribution to journalReview article

Abstract

Background: Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity. Objectives: The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013). Selection criteria: Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM. Data collection and analysis: Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy. Main results: We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review. Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants). Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment. Authors' conclusions: These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.

Original languageEnglish (US)
Article numberCD000942
JournalCochrane Database of Systematic Reviews
Volume2014
Issue number3
DOIs
StatePublished - Mar 30 2014
Externally publishedYes

Fingerprint

Third Pregnancy Trimester
Confidence Intervals
Odds Ratio
Morbidity
Umbilical Arteries
Deceleration
Maternal Mortality
Perinatal Mortality
Amniotic Fluid
Preterm Premature Rupture of the Membranes
Patient Selection
Rupture
Sepsis
Parturition
Pregnancy
Lung
Membranes

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Amnioinfusion for third trimester preterm premature rupture of membranes. / Hofmeyr, G. Justus; Eke, Ahizechukwu; Lawrie, Theresa A.

In: Cochrane Database of Systematic Reviews, Vol. 2014, No. 3, CD000942, 30.03.2014.

Research output: Contribution to journalReview article

@article{2c9fe23045af43a4ab9ad088d99995df,
title = "Amnioinfusion for third trimester preterm premature rupture of membranes",
abstract = "Background: Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity. Objectives: The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013). Selection criteria: Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM. Data collection and analysis: Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy. Main results: We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review. Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95{\%} confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95{\%} CI 0.30 to 0.91; one trial, 86 participants). Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95{\%} CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95{\%} CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95{\%} CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95{\%} CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95{\%} CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment. Authors' conclusions: These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.",
author = "Hofmeyr, {G. Justus} and Ahizechukwu Eke and Lawrie, {Theresa A.}",
year = "2014",
month = "3",
day = "30",
doi = "10.1002/14651858.CD000942.pub3",
language = "English (US)",
volume = "2014",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Amnioinfusion for third trimester preterm premature rupture of membranes

AU - Hofmeyr, G. Justus

AU - Eke, Ahizechukwu

AU - Lawrie, Theresa A.

PY - 2014/3/30

Y1 - 2014/3/30

N2 - Background: Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity. Objectives: The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013). Selection criteria: Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM. Data collection and analysis: Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy. Main results: We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review. Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants). Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment. Authors' conclusions: These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.

AB - Background: Preterm premature rupture of membranes (PPROM) is a leading cause of perinatal morbidity and mortality. Amnioinfusion aims to restore amniotic fluid volume by infusing a solution into the uterine cavity. Objectives: The objective of this review was to assess the effects of amnioinfusion for PPROM on perinatal and maternal morbidity and mortality. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (2 December 2013). Selection criteria: Randomised trials of amnioinfusion compared with no amnioinfusion in women with PPROM. Data collection and analysis: Three review authors independently assessed trials for inclusion. Two review authors independently assessed trial quality and extracted data. Data were checked for accuracy. Main results: We included five trials, of moderate quality, but we only analysed data from four studies (with a total of 241 participants). One trial did not contribute any data to the review. Transcervical amnioinfusion improved fetal umbilical artery pH at delivery (mean difference 0.11; 95% confidence interval (CI) 0.08 to 0.14; one trial, 61 participants) and reduced persistent variable decelerations during labour (risk ratio (RR) 0.52; 95% CI 0.30 to 0.91; one trial, 86 participants). Transabdominal amnioinfusion was associated with a reduction in neonatal death (RR 0.30; 95% CI 0.14 to 0.66; two trials, 94 participants), neonatal sepsis (RR 0.26; 95% CI 0.11 to 0.61; one trial, 60 participants), pulmonary hypoplasia (RR 0.22; 95% CI 0.06 to 0.88; one trial, 34 participants) and puerperal sepsis (RR 0.20; 95% CI 0.05 to 0.84; one trial, 60 participants). Women in the amnioinfusion group were also less likely to deliver within seven days of membrane rupture (RR 0.18; 95% CI 0.05 to 0.70; one trial, 34 participants). These results should be treated with circumspection as the positive findings were mainly due to one trial with unclear allocation concealment. Authors' conclusions: These results are encouraging but are limited by the sparse data and unclear methodological robustness, therefore further evidence is required before amnioinfusion for PPROM can be recommended for routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84907396652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907396652&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD000942.pub3

DO - 10.1002/14651858.CD000942.pub3

M3 - Review article

C2 - 24683009

AN - SCOPUS:84907396652

VL - 2014

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 3

M1 - CD000942

ER -